The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …

The liver is the sixth most common site of primary cancer in humans, and generally arises in
a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

HCC is one of the most common cancers worldwide, and the third leading cause of cancer‐
related death globally. HCC comprises nearly 90% of all cases of primary liver cancer …

Caloric excess and sedentary lifestyle have led to a global epidemic of obesity and
metabolic syndrome. The hepatic consequence of metabolic syndrome and obesity …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor
for end-stage liver diseases with no available therapies. Dysregulated immune responses …

The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

The prevalence of liver cancer is constantly rising, with increasing incidence and mortality in
Europe and the USA in recent decades. Among the different subtypes of liver cancers …

Incidence of hepatocellular carcinoma (HCC) is on the rise due to the prevalence of chronic
hepatitis and cirrhosis. Although there are surgical and chemotherapy treatment avenues …